** Drugmaker Amneal Pharmaceuticals' AMRX.O shares rise 1.4% to $8.5 premarket
** Co forecasts 2025 revenue in the range of $3.0 bln to $3.1 bln, higher than analysts' estimate of $2.9 bln, as per data compiled by LSEG
** AMRX posts Q4 revenue of $731 mln vs analysts' estimate of $707.6 mln
** Co reports Q4 adj profit of 12 cents/share vs analysts' estimates of 15 cents/share
** AMRX expects 2025 adj profit in the range of 65 cents/share to 70 cents/share, analysts on average expect 2025 adj profit of 73 cents/share
** Stock has risen 46.8% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。